TRAF3 interacting protein 2 (TRAF3IP2)

TRAF3 interacting protein 2 (TRAF3IP2) is a multifunctional adapter protein and E3 ubiquitin ligase that regulates immune and inflammatory signaling pathways, particularly mediating responses through the interleukin-17 (IL-17) receptor by activating downstream NF-kappa-B and MAP kinase signaling[1][3]. TRAF3IP2 interacts with multiple tumor necrosis factor receptor-associated factor (TRAF) proteins and is essential for the formation of signaling complexes that drive innate and adaptive immune responses, especially the Th17 pathway[1][2]. Genetic variants in TRAF3IP2 are associated with increased susceptibility to autoimmune and inflammatory diseases, most notably psoriatic arthritis and psoriasis[1][2]. TRAF3IP2 is highly conserved, widely expressed in immune and epithelial cells, and is a critical bridge connecting surface cytokine receptors to intracellular signal transduction cascades associated with inflammation and host defense[1][2][3][5].

Other names

ACT1CIKSAdapter protein CIKSNuclear factor NF-kappa-B activator 1C6orf2C6orf4C6orf5C6orf6CANDF8PSORS13E3 ubiquitin ligase TRAF3IP2E3 ubiquitin-protein ligase CIKS

Drugs (such as TNF inhibitors) affect downstream activation pathways involving TRAF3IP2, reducing NF-kappa-B-mediated inflammation